Reckitt Benckiser Group PLC Directorate Change (5986S)
26 Giugno 2018 - 11:15AM
UK Regulatory
TIDMRB.
RNS Number : 5986S
Reckitt Benckiser Group PLC
26 June 2018
Dr. Mehmood Khan to join RB Board, strengthening further its
scientific and sustainability focus
June 26, 2018, Slough UK -Today RB is pleased to announce the
appointment of Dr. Mehmood Khan to the Board, with effect from July
1(st) 2018.
Dr. Khan is the Vice Chairman and Chief Scientific Officer,
Global Research and Development, at PepsiCo, the global food and
beverage company with net revenues of over $63 billion.
In his role, Dr. Khan oversees the PepsiCo global Performance
with Purpose sustainability initiatives, inspired by the belief
that business success is inextricably linked to the sustainability
of the world. Dr. Khan also leads PepsiCo's R&D efforts,
creating breakthrough innovations in food, beverages and
nutrition.
Prior to joining PepsiCo, Dr. Khan was President, Takeda Global
Research & Development Center, overseeing Takeda
Pharmaceuticals Company's worldwide R&D efforts. Previously,
Dr. Khan was a faculty member at the Mayo Clinic and Mayo Medical
School in Rochester, Minnesota, serving as Director of the
Diabetes, Endocrine and Nutritional Trials Unit in the
endocrinology division. He earned his medical degree from the
University of Liverpool Medical School and is a Fellow of the Royal
College of Physicians, London.
Dr. Khan is also an independent director of biopharmaceutical
company CorMedix.
Commenting on the appointment, Chris Sinclair, Chairman of the
Board of RB, said "I am delighted that Mehmood has agreed to join
the Board. He brings enormous experience as a medical practitioner
and researcher, and in the application of science to the
development of consumer products, in particular in the field of
nutrition. He is also a seasoned executive on the management team
of a global consumer products company, with extensive experience in
both developing and developed markets. I am confident that he will
make a significant contribution to RB and the Board."
Dr. Khan will also join RB's Corporate Responsibility,
Sustainability, Ethics and Compliance Committee which is chaired by
Pam Kirby.
The Company confirms that there is no further information to be
disclosed under the requirements of Listing Rule 9.6.13R in
relation to Dr. Khan's appointment.
For further information, please contact:
Reckitt Benckiser +44 (0)1753 217800
Patty O'Hayer
Finsbury +44 (0)207 251 3801
Catherine Boyle
Reckitt Benckiser Group plc's LEI code is
5493003JFSMOJG48V108
About RB
RB is the global leading consumer health, hygiene and home
company. Driven by a purpose to build healthier lives and happier
homes, RB has operations in over 60 countries. From the foundations
of wellness and infant nutrition, to the fundamentals of a hygienic
home, our global brands help people live healthier, happier
lives.
RB has world leading Powerbrands which include household names
such as Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex,
Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang,
Mortein, Finish, Vanish, Calgon, Woolite and Air Wick.
RB's unique culture is at the heart of its success. Its drive to
achieve, passion to outperform and commitment to quality and
scientific excellence are manifested in the work of over 40,000 RB
employees worldwide.
For more information visit www.rb.com
*RB is the trading name of the Reckitt Benckiser group of
companies
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAPGUGGQUPRUBQ
(END) Dow Jones Newswires
June 26, 2018 05:15 ET (09:15 GMT)
Grafico Azioni Reckitt Benckiser (LSE:RKT)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Reckitt Benckiser (LSE:RKT)
Storico
Da Apr 2023 a Apr 2024